Equity Profile

TGTX

TG THERAPEUTICS INC

Health CareBiotechnology$6.1B

Mar8Fri

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EST

Company Snapshot

TG Therapeutics Inc is a biotechnology company focused on developing innovative treatments for cancer and autoimmune diseases. With a market cap of $6 billion, the company plays a significant role in the health care sector, particularly in advancing therapies that could improve patient outcomes.

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of a company's profitability and will help investors gauge TG Therapeutics' financial health this quarter.

N/A

Revenue Growth

Revenue growth is crucial for understanding the company's market traction and the success of its product pipeline.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

TGTX Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

38%

Avg EPS Surprise

+113.34%

Avg Stock Reaction

+1.32%

Last Quarter Recap

In the last quarter, TG Therapeutics reported an EPS of $0.12, which was significantly below the expected $0.23, resulting in a 16.26% stock increase the following day. This suggests that despite the earnings miss, investors reacted positively, possibly due to other factors.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, investors are cautiously optimistic about TG Therapeutics' upcoming earnings, given the company's innovative pipeline and potential for growth. However, the recent earnings misses may lead to skepticism regarding future performance.

Bull Case

If the company reports strong clinical trial results and improved revenue, it could validate investor confidence and drive the stock higher.

Bear Case

Conversely, another earnings miss or disappointing trial results could lead to further declines in stock price, as investors may lose faith in the company's growth prospects.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the EPS and revenue figures for this quarter?

Given the company's recent performance, these figures will be critical in determining investor sentiment and confidence moving forward.

Are there any updates on ongoing clinical trials?

Positive updates could significantly boost the stock price, while negative news could have the opposite effect.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential impact of positive clinical trial results, which could significantly boost revenue and investor sentiment.

Supporting Evidence

Options are pricing a 3.57% move, but the stock has averaged a 12.28% move historically, indicating potential for a larger reaction.

The recent stock price increases following earnings misses suggest that investors may be looking for reasons to remain optimistic.

Key Risk

If clinical trial results exceed expectations, it could shift the narrative and lead to a significant stock price increase.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter revolves around the company's ability to turn around its recent earnings performance and the potential impact of its clinical trials on future growth.

Bull Confirmed If

A positive EPS surprise of at least $0.25 and strong revenue growth would confirm the bull case.

Bear Confirmed If

An EPS miss below $0.10 and negative updates on clinical trials would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±3.57%

Historical Avg

±12.3%

Pricing cheap

The options market is pricing in a modest move of about 3.57%, which is significantly lower than the historical average of 12.28%, indicating a potentially muted reaction to the earnings report.

Options are pricing ±3.6% while TGTX has averaged ±12.3% over the last 8 prints — setup is pricing cheap.

Detail

ATM IV

0.5%

30d HV

59.8%

Calls (49K)P/C Ratio: 0.50Puts (29K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing cheap setup in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 3.6%, with a raw directional average of -1.3% (modestly negative historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If TG Therapeutics beats expectations, history suggests the stock could rise by around 10.28%, confirming a positive outlook for the company.

In-Line / Cautious

If results are in line with expectations, the stock may see a muted reaction, reflecting ongoing investor caution.

Miss

Should the company miss earnings expectations again, history suggests a potential decline of around 4.05%, further shaking investor confidence.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the status of ongoing clinical trials and their expected timelines.
2Details on revenue growth and any changes in guidance for the upcoming quarters.
3Management's commentary on market conditions and competitive landscape.
4Insights into potential partnerships or collaborations that could enhance growth.
5Any changes in operational efficiency or cost management strategies.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Ross Stores, Inc.

Company Snapshot

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of a company's profitability and will help investors gauge TG Therapeutics' financial health this quarter.

N/A

Revenue Growth

Revenue growth is crucial for understanding the company's market traction and the success of its product pipeline.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

TGTX Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

38%

Avg EPS Surprise

+113.34%

Avg Stock Reaction

+1.32%

Last Quarter Recap

Management Promises & Guidance

Expectations

Wall Street Expectations

Bull Case

If the company reports strong clinical trial results and improved revenue, it could validate investor confidence and drive the stock higher.

Bear Case

Conversely, another earnings miss or disappointing trial results could lead to further declines in stock price, as investors may lose faith in the company's growth prospects.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the EPS and revenue figures for this quarter?

Given the company's recent performance, these figures will be critical in determining investor sentiment and confidence moving forward.

Are there any updates on ongoing clinical trials?

Positive updates could significantly boost the stock price, while negative news could have the opposite effect.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential impact of positive clinical trial results, which could significantly boost revenue and investor sentiment.

Supporting Evidence

Options are pricing a 3.57% move, but the stock has averaged a 12.28% move historically, indicating potential for a larger reaction.

The recent stock price increases following earnings misses suggest that investors may be looking for reasons to remain optimistic.

Key Risk

If clinical trial results exceed expectations, it could shift the narrative and lead to a significant stock price increase.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter revolves around the company's ability to turn around its recent earnings performance and the potential impact of its clinical trials on future growth.

Bull Confirmed If

A positive EPS surprise of at least $0.25 and strong revenue growth would confirm the bull case.

Bear Confirmed If

An EPS miss below $0.10 and negative updates on clinical trials would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±3.57%

Historical Avg

±12.3%

Pricing cheap

The options market is pricing in a modest move of about 3.57%, which is significantly lower than the historical average of 12.28%, indicating a potentially muted reaction to the earnings report.

Options are pricing ±3.6% while TGTX has averaged ±12.3% over the last 8 prints — setup is pricing cheap.

Detail

ATM IV

0.5%

30d HV

59.8%

Calls (49K)P/C Ratio: 0.50Puts (29K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing cheap setup in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If TG Therapeutics beats expectations, history suggests the stock could rise by around 10.28%, confirming a positive outlook for the company.

In-Line / Cautious

If results are in line with expectations, the stock may see a muted reaction, reflecting ongoing investor caution.

Miss

Should the company miss earnings expectations again, history suggests a potential decline of around 4.05%, further shaking investor confidence.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the status of ongoing clinical trials and their expected timelines.
2Details on revenue growth and any changes in guidance for the upcoming quarters.
3Management's commentary on market conditions and competitive landscape.
4Insights into potential partnerships or collaborations that could enhance growth.
5Any changes in operational efficiency or cost management strategies.